Chronic Kidney Disease

In this video perspective, George L. Bakris, MD, discusses the long-term influence of hypertension on patients with chronic kidney disease.

The dual SGLT1/SGLT2 inhibitor sotagliflozin is effective at reducing risk for heart failure, myocardial infarction and stroke while also slowing progression of chronic kidney disease, according to findings from two large clinical trials.

In this video exclusive, Richard E. Pratley, MD, talks with Deepak L. Bhatt, MD, MPH, about results and implications of the SOLOIST and SCORED trials of the SGLT1/SGLT2 inhibitor sotogliflozin vs. placebo in adults with type 2 diabetes.

A retrospective cohort study of U.S. veterans with advanced chronic kidney disease demonstrated that laxative use within the 2-year period before dialysis initiation did not significantly impact eGFR decline.

A meta-analysis revealed the presence of sarcopenia increased the risk for death by 143% in patients with nondialysis-dependent chronic renal disease.

Use of potentially inappropriate medications, as defined by the American Geriatrics Society Beers Criteria, was linked to an increased risk for hospitalizations, falls and mortality in adults with chronic kidney disease.

A mixed-effects models study showed the importance of diction and how it can influence chronic kidney disease awareness. Differing terminology impacted patients’ understanding of their condition and treatment options, researchers noted.

Results of a questionnaire administered to patients with advanced chronic kidney disease revealed intentions to pursue vascular access were heavily informed by patient perception of the benefits early access creation might provide.

Patients with chronic kidney disease and iron-deficiency anemia saw statistically significant increases in hemoglobin levels following treatment with oral ferric maltol, according to data from a phase 3 randomized placebo-controlled trial.

Recently published findings suggested that clinicians overlooked the prevalence of chronic kidney disease in patient populations that were traditionally considered low risk.